This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Metan, G.
Right arrow Articles by Uzun, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metan, G.
Right arrow Articles by Uzun, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2005, p. 3980-3981, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3980-3981.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Impact of Initial Antimicrobial Therapy in Patients with Bloodstream Infections Caused by Stenotrophomonas maltophilia


arrow
LETTER
 
The impact of inappropriate initial antimicrobial therapy on the outcomes of patients with bloodstream infections caused by antibiotic-resistant gram-negative bacilli is not well defined. Recently, in an interesting study by Kang et al., inappropriate initial antimicrobial therapy was found to be associated with an adverse outcome, particularly in patients with a high-risk source of bacteremia caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., and Pseudomonas aeruginosa (1). In addition to the source of bacteremia, presentation with septic shock, P. aeruginosa infection, and an increasing acute physiology, age, and chronic health evaluation (APACHE II) score were poor prognostic factors in this study.

Stenotrophomonas maltophilia is an emerging nosocomial pathogen with a tendency to be resistant to several antibiotics commonly used to treat nosocomial infections. Although a recent study reported no significant difference in the outcomes of patients who received appropriate therapy and outcomes of patients who received inappropriate therapy (2), at least two case-controlled studies described inappropriate therapy as an independent risk factor for mortality (3, 4).

At our center (Hacettepe University School of Medicine Hospital, a 1,000-bed tertiary-care teaching hospital), we evaluated the factors that influenced the outcomes in patients with bacteremia caused by S. maltophilia. We retrospectively reviewed the reports of our clinical microbiology laboratory to identify the study patients during a six-year period from 1998 to 2004. Case patients were defined as those who were >16 years of age, had at least one blood culture positive for S. maltophilia, and had clinical signs of systemic infection. The mortality rate 30 days after the onset of bacteremia was used as the main outcome measure. Appropriate therapy was defined as one or more agents active against S. maltophilia, given adequate dose and route of administration, not later than 24 h after the blood culture was obtained. All statistical analyses were performed by using SPSS software (version 10.0; SPSS, Chicago, IL). Numerical data were reported (medians and interquartile ranges). To test for the differences between quantitative variables between appropriate and inappropriate therapies, independent-sample t tests were used for normally distributed variables. Differences between categorical variables were analyzed by the chi-square test with the continuity correction or the Fisher exact test where appropriate.

Fifty-six patients with S. maltophilia bacteremia were identified. A total of 41 patients were included in the analysis. Fifteen cases whose medical records contained missing data were excluded from the study. The overall 30-day mortality rate was 31.7%. The patients who died within 30 days after the onset of S. maltophilia bacteremia had a longer duration of hospitalization and a higher rate of intensive care unit stay (at the time of initial bacteremia), as well as an increased need for mechanical ventilation and presentation with septic shock (Table 1). Twelve (29.2%) patients had received inappropriate therapy. Eight (66.7%) patients who were treated inappropriately died, compared to 5 (17.2%) of 29 who died though they received an appropriate antibiotic(s). Six of 8 (75.0%) patients who died were on carbapenems when S. maltophilia bacteremia developed.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Demographic characteristics of the patients with bloodstream infection caused by S. maltophilia

In this limited study, we have shown a higher mortality rate for the bacteremic patients who did not receive appropriate therapy against S. maltophilia. We believe this issue should be further evaluated by case-controlled studies with a higher number of patients who had similar comorbid factors. In addition, the practicing physician should consider S. maltophilia as the causative organism in a patient who deteriorates under carbapenem therapy.


arrow
ACKNOWLEDGMENTS
 
We thank Mine Durusu for statistical analysis.


arrow
REFERENCES
 
    1
  1. Kang, C.-I., S.-H. Kim, W. B. Park, et al. 2005. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother. 49:760-766.[Abstract/Free Full Text]
    2. 2
  2. Lai, C. H., C. Y. Chi, H. P. Chen, et al. 2004. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J. Microbiol. Immunol. Infect. 37:350-358.[Medline]
    3. 3
  3. Micozzi, A., M. Venditti, M. Monaco, A. Friedrich, F. Taglietti, S. Santilli, and P. Martino. 2000. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin. Infect. Dis. 31:705-711.[CrossRef][Medline]
    4. 4
  4. Senol, E., J. DesJardin, P. C. Stark, L. Barefoot, and D. R. Snydman. 2002. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin. Infect. Dis. 34:1653-1656.[CrossRef][Medline]
Gokhan Metan*
Omrum Uzun
Division of Infectious Diseases
Department of Internal Medicine
Hacettepe University School of Medicine

* Phone: 90 312 305 15 60, E-mail: metan{at}hacettepe.edu.tr

Antimicrobial Agents and Chemotherapy, September 2005, p. 3980-3981, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3980-3981.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Metan, G.
Right arrow Articles by Uzun, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metan, G.
Right arrow Articles by Uzun, O.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»